CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗与肿瘤微环境：当前挑战与机遇
英文原题：CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.
查看英文原题
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤患者中已展现出显著疗效，但其成功受到肿瘤微环境（TME）固有障碍的制约，尤其是在实体瘤中，该疗法尚未取得突破。本文就TME中构成CAR-T 细胞疗法疗效障碍的特征进行更新综述并展望未来方向，包括代谢燃料竞争、浸润的物理屏障以及免疫抑制因素。随后我们讨论正在临床前开发或临床研究中、旨在克服这些障碍的新颖且有前景的策略。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in individuals with hematological malignancies, but its success has been hindered by barriers intrinsic to the tumor microenvironment (TME), particularly for solid tumors, where it has yet to make its mark. In this article, we provide an updated review and future perspectives on features of the TME that represent barriers to CART cell therapy efficacy, including competition for metabolic fuels, physical barriers to infiltration, and immunosuppressive factors.
We then discuss novel and promising strategies to overcome these obstacles that are in preclinical development or under clinical investigation.
论文信息
- 作者
- Kankeu Fonkoua LA、Sirpilla O、Sakemura R、Siegler EL、Kenderian SS
- 单位
- T Cell Engineering Laboratory, Mayo Clinic, Rochester, MN, USA.United States
- 文献类型
- 综述
- 期刊
- Molecular therapy oncolytics2022 Jun 16
- 原文标识
- PubMed 35434273 · DOI 10.1016/j.omto.2022.03.009
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →